HRMY - NASDAQ

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ

$32.10

+0.91%

HealthcareBiotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.86B

EPS2.7600

P/E Ratio11.63

Earnings Date08/04/2026

hrmy

Operating Income

Last Annual Value

208.47M

3-Year CAGR

20%

5-Year CAGR

65%

10-Year CAGR

22%

Adjust for Inflation

Harmony Biosciences Holdings, Inc. Competitors Analysis of Operating Income

HRMY · NASDAQ

Company	Operating Income	CAGR 3Y	CAGR 5Y	CAGR 10Y
Harmony Biosciences Holdings, Inc. NASDAQ:HRMY	208.47M	2.8%	19.0%	N/A
MannKind Corporation NASDAQ:MNKD	38.80M	64.7%	N/A	-5.4%
Biohaven Ltd. NYSE:BHVN	-745.38M	N/A	N/A	N/A
Sionna Therapeutics, Inc. NASDAQ:SION	-88.98M	N/A	N/A	N/A
Celldex Therapeutics, Inc. NASDAQ:CLDX	-287.40M	N/A	N/A	N/A
Janux Therapeutics, Inc. NASDAQ:JANX	-157.67M	N/A	N/A	N/A
Nuvation Bio Inc. NYSE:NUVB	-213.06M	N/A	N/A	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	-315.47M	N/A	N/A	N/A

Harmony Biosciences Holdings, Inc. Fair Value Envelope

HRMY · NASDAQ

Our analysis suggests that HRMY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.1, this represents a potential HIDDEN relative to our calculated worth for Harmony Biosciences Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $32.1

Related Guides

Blog Categories

Continue your HRMY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.